> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regeneron Halts Phase 1/2a Eye Disease Trial Due to Safety Review
- URL: https://www.fdaweb.com/regeneron-halts-phase-1-2a-eye-disease-trial-due-to-safety-review/
- Published: 2026-08-17T12:00:00.000Z
- Updated: 2026-09-14T13:45:13.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161635

Regeneron Pharmaceuticals has stopped a Phase 1/2a clinical trial of experimental anti-CD3 monoclonal antibody REGN7041 in patients with noninfectious uveitis after a safety event prompted the company to reassess the drug's risk-benefit profile, according to a [*clinicaltrials.gov*](https://clinicaltrials.gov/study/NCT07218770?ref=fdaweb.com) posting.

Regeneron said the decision to terminate the trial followed a review of a safety event observed during the study. “Regeneron voluntarily terminated the Phase 1/2a TITAN study” following an updated risk-benefit assessment prompted by the safety event, a company spokesperson told *Fierce Biotech*.

Regeneron investigated the incident but said that “the underlying cause has not been identified.” The company did not disclose the nature or severity of the adverse event or provide additional details about the future development of REGN7041.

REGN7041 targets CD3, a protein expressed on the surface of T cells. CD3 has been a longstanding target for immunotherapies, although most recent drug development has focused on bispecific antibodies that engage CD3 along with a second target.